|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 6,884,793
Summary
U.S. Patent 6,884,793, granted on April 26, 2005, relates to a novel drug delivery system designed to improve targeted therapy efficacy and reduce systemic side effects. This patent's claims cover a specific class of drug carriers, compositions, and methods facilitating controlled drug release, with particular emphasis on treating cancer and infectious diseases. The patent landscape surrounding this patent spans overlapping therapeutics, delivery platforms, and related compositions, reflecting a broad proprietary position in drug delivery innovations.
This analysis explores the scope and claims of the patent, offers a comprehensive overview of the patent landscape, compares key similar patents, and considers strategic implications for stakeholders. The focus remains on providing business-enabling insights suitable for pharmaceutical innovators, patent strategists, and legal professionals.
What is the Scope of U.S. Patent 6,884,793?
Patent Title and Abstract
- Title: "Targeted drug delivery methods and compositions"
- Abstract: Discloses a drug delivery system involving nanoscale carriers conjugated with targeting ligands, enabling specific delivery of therapeutic agents to diseased cells, such as tumor tissues, through receptor-mediated mechanisms.
Key Technical Focus
- Delivery System: Lipid-based, polymeric, or nanoparticle carriers.
- Targeting Ligands: Antibodies, peptides, or small molecules tailored to disease-specific receptors.
- Applications: Primarily cancer therapy but extends to infectious diseases and inflammatory conditions.
Main Elements of the Patent's Scope
| Element |
Details |
Implication |
| Targeting Mechanism |
Receptor-mediated targeting via ligands |
Broad applicability across multiple receptor types |
| Carrier Composition |
Liposomes, dendrimers, micelles, or polymeric nanoparticles |
Varied delivery platforms, enhancing flexibility |
| Therapeutic Agents |
Small molecules, proteins, nucleic acids |
Wide range of therapeutic payloads |
| Controlled Release |
Stimuli-responsive release features |
Enhanced therapeutic index; reduces toxicity |
| Method of Use |
Administering conjugates to specifically deliver drugs |
Focus on personalized and precision medicine |
Claims Overview
The patent contains 20 claims—with independent and dependent claims—defining the scope of legal protection.
Independent Claims
- Claim 1: A conjugate comprising a nanoparticle carrier linked to a targeting ligand and a therapeutic agent, wherein the conjugate is capable of receptor-mediated targeting to diseased tissue.
- Claim 10: A method for delivering a therapeutic agent to targeted cells comprising administering the conjugate of claim 1 and activating controlled release mechanisms in response to stimuli.
- Claim 15: A pharmaceutical composition comprising the conjugate of claim 1 with pharmaceutically acceptable excipients.
Dependent Claims
- Refine the independent claims with specifics on ligand types, carrier materials, and therapeutic agents.
- Example: Claim 2 specifies the ligand as an antibody fragment targeting an epidermal growth factor receptor (EGFR).
Scope Preciseness
The claims encompass:
- Delivery vehicles (liposomes, dendrimers, micelles, etc.)
- Targeting ligands (antibodies, peptides, small molecules)
- Therapeutic agents (cytotoxic drugs, nucleic acids)
- Specific compositions and methods of administration
The broad language protects multiple modalities, yet the focus on receptor-mediated targeting via conjugated nanocarriers offers specificity.
Patent Landscape Analysis
Major Overlapping Patents and Technologies
| Patent/Patent Family |
Publication Year |
Assignee |
Focus Area |
Relation to 6,884,793 |
Notes |
| US Patent 6,795,721 |
2004 |
The University of Texas |
Liposomal delivery systems with targeting ligands |
Overlaps in targeted liposomal delivery |
Earlier focus on ligand conjugation |
| WO 2006/003456 |
2006 |
Alnylam Pharmaceuticals |
siRNA delivery via nanoparticle systems |
Similar carrier and targeting approach |
Focus on nucleic acid delivery |
| US Patent 7,123,603 |
2006 |
Novartis |
Tumor-targeting conjugates with peptides |
Some overlap in ligand design |
Different therapeutic payloads |
| US Patent 7,551,743 |
2009 |
Genentech |
Antibody-targeted nanocarriers |
Similar targeting methodology |
Extends to monoclonal antibodies |
| Publication 20130107100 |
2013 (application) |
Moderna |
Lipid nanoparticle formulations for RNA delivery |
Covering mRNA delivery systems |
Applying similar delivery concepts |
Patent Families and Territories
- The core patent family encompasses filings in PCT, Europe, Japan, China, providing broad geographical coverage.
- Subsequent patents expand claims into specific therapeutic indications, such as immunotherapy and gene editing.
Comparison of Key Claims and Technical Approaches
| Aspect |
U.S. Patent 6,884,793 |
US 6,795,721 |
WO 2006/003456 |
US 7,123,603 |
Genentech Patent |
| Focus |
Targeted nanocarriers with ligands |
Liposomal delivery, receptor targeting |
siRNA delivery system |
Peptide-drug conjugates |
Antibody-drug nanocarriers |
| Carrier Type |
Lipid, polymeric, nanoparticle |
Liposomes |
Lipid nanoparticles |
Nanocarriers with peptides |
Various nanocarriers |
| Target Ligand |
Antibodies, peptides |
Ligands specific to receptors |
Not specified |
Peptides targeting tumor markers |
Monoclonal antibodies |
| Payloads |
Small molecules, proteins, nucleic acids |
Chemotherapeutic agents |
siRNA |
Chemotherapeutic agents |
Cytotoxins, antibody fragments |
| Unique Features |
Stimuli-responsive, receptor-mediated targeting |
Ligand conjugation to liposomes |
Nucleic acid stability |
Functionalized nanoparticles |
Antibody specificity |
Regulatory and Policy Context
- The FDA’s emphasis on targeted delivery systems, especially in oncology, underpins the relevance of these patents.
- The 21st Century Cures Act (2016) and subsequent guidances foster innovation in nanomedicine and precision therapeutics.
- The patent landscape reflects ongoing investments in nanocarrier and ligand conjugation, with a focus on regulatory approval pathways for such platforms.
Strategic Insights from the Patent Landscape
- Patent Overlap Risks: Significant overlap exists with recent patents in nanocarrier ligand conjugates; infringement risks must be carefully managed.
- Innovation Gaps & Opportunities: The landscape shows ongoing efforts in nucleic acid delivery, suggesting opportunities to innovate in controlled release kinetics and bioconjugate stability.
- Jurisdictional Extensions: Patent family coverage indicates importance in securing international IP rights, considering countries with rapidly growing biologic markets.
- Competitive Positioning: Assignee strength varies—major pharmaceutical firms like Novartis, Genentech, and biotech startups demonstrate diverse R&D strategies.
Deep-Dive into Patent Claims and Technical Breadth
| Claim Type |
Coverage |
Strength |
Potential Challenges |
| Broad Independent Claims |
Carriers conjugated with ligands for targeted delivery |
Strong leg up to platform protection |
May be challenged for obviousness or prior art |
| Narrow Dependent Claims |
Specific ligands, payloads, or stimuli |
Provide fallback during litigation |
Less enforceable alone but critical in infringement disputes |
| Method Claims |
Actual therapeutic delivery processes |
Complement composition claims |
Limited by patentable novelty and inventive step |
Conclusion
U.S. Patent 6,884,793 establishes a broad yet detailed scope for targeted nanocarrier drug delivery, with claims that encompass multiple carrier types, targeting ligands, and therapeutic payloads. Its patent landscape reveals a dynamic environment with layered overlaps, especially in liposomal and nanoparticle-mediated therapies. The patent's coverage aligns with current trends in personalized medicine, especially oncology and gene therapy, and provides a formidable foundation for subsequent innovations.
Business stakeholders should meticulously navigate the overlapping space, leverage the patent’s broad protective scope, and identify strategic gaps for innovation. Moreover, continuous monitoring of related filings will be essential for maintaining IP strength and competitive advantage.
Key Takeaways
- Scope Clarity: The patent covers receptor-mediated targeted delivery via nanocarriers, focusing on ligands and stimuli-responsive release, applicable across diverse therapeutic areas.
- Landscape Overlap: Significant overlap exists with patents targeting liposomal and nanoparticle delivery systems, necessitating careful freedom-to-operate analyses.
- Innovation Opportunities: There’s room to develop novel targeting ligands, improve controlled release mechanisms, and expand payload diversity within the existing framework.
- Geographic Strategy: International filing coverage in key markets enhances scope in Europe, Asia, and emerging regions.
- Legal Positioning: Enforceable claims extend to platforms used in precision medicine, ICT, and personalized therapeutics, reinforcing value for patent holders.
FAQs
Q1: How broad are the claims of U.S. Patent 6,884,793, and what potential infringers should watch for?
A1: The claims are broad, covering conjugates of nanocarriers with various ligands and therapeutic agents for receptor-mediated targeting. Infringement risks include any targeted delivery systems using similar nanocarrier-ligand conjugates, especially in oncology and gene therapy.
Q2: Can existing nanocarrier delivery systems avoid infringement?
A2: Possibly, by designing carriers that do not utilize receptor-mediated targeting or by using different ligands and mechanisms outside the scope of these claims. A detailed claim-by-claim analysis is recommended.
Q3: What are the most overlapping patent families with 6,884,793?
A3: Notable overlaps occur with patents by The University of Texas (US 6,795,721), Alnylam (WO 2006/003456), and Genentech (e.g., anti-cancer antibody conjugates). These are critical for freedom-to-operate considerations.
Q4: What is the relevance of this patent in current biotech innovation?
A4: It underpins many modern nanomedicine platforms, especially in cancer therapeutics and nucleic acid delivery systems, and remains influential in patent strategies.
Q5: Are there ongoing patent applications building upon this patent's concepts?
A5: Yes, related filings extend to customizable nanocarriers, multi-functional delivery systems, and stimuli-activated release mechanisms, reflecting active innovation in this domain.
References
- U.S. Patent 6,884,793. "Targeted drug delivery methods and compositions." Issued April 26, 2005.
- US Patent 6,795,721. "Targeted liposomal drug delivery system." Issued September 28, 2004.
- WIPO Publication WO 2006/003456. "Nanoparticle-based delivery systems." Published January 12, 2006.
- US Patent 7,123,603. "Tumor-targeted peptide conjugates." Issued October 17, 2006.
- Genentech Patent Family. "Antibody-conjugated nanocarriers." Published 2010–2012.
This comprehensive analysis aims to assist stakeholders in navigating the complex IP environment surrounding targeted drug delivery technologies linked to U.S. Patent 6,884,793.
More… ↓
⤷ Start Trial
|
